Esperion Therapeutics (ESPR) Non-Current Deffered Revenue (2019 - 2022)

Esperion Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $211000.0 in Q2 2022.

• For the quarter ending Q2 2022, Non-Current Deffered Revenue fell 80.04% year-over-year to $211000.0; the trailing twelve-month figure through Jun 2022 stood at $211000.0 (down 80.04% YoY), and the FY2021 full-year result was $634000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue for Q2 2022 stood at $211000.0, down from $422000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $1.1 million in Q2 2021, with the low at $211000.0 in Q2 2022.
• Historically, Non-Current Deffered Revenue has averaged $637333.3 across 3 years, with a median of $644500.0 in 2019.
• The largest YoY upside for Non-Current Deffered Revenue was 80.04% in 2022 against a maximum downside of 80.04% in 2022.
• Esperion Therapeutics' Non-Current Deffered Revenue stood at $655000.0 in 2019, then retreated by 3.21% to $634000.0 in 2021, then tumbled by 66.72% to $211000.0 in 2022.
• The last three Non-Current Deffered Revenue figures came in at $211000.0 (Q2 2022), $422000.0 (Q1 2022), and $634000.0 (Q4 2021), per Business Quant data.